377 related articles for article (PubMed ID: 33520115)
1. Reversing oncogenic transformation with iron chelation.
Abdelaal G; Veuger S
Oncotarget; 2021 Jan; 12(2):106-124. PubMed ID: 33520115
[TBL] [Abstract][Full Text] [Related]
2. Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.
Lane DJ; Mills TM; Shafie NH; Merlot AM; Saleh Moussa R; Kalinowski DS; Kovacevic Z; Richardson DR
Biochim Biophys Acta; 2014 Apr; 1845(2):166-81. PubMed ID: 24472573
[TBL] [Abstract][Full Text] [Related]
3. Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines.
Abdelaal G; Carter A; Panayiotides MI; Tetard D; Veuger S
Front Mol Biosci; 2022; 9():1005092. PubMed ID: 36213122
[TBL] [Abstract][Full Text] [Related]
4. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation.
Le NT; Richardson DR
Blood; 2004 Nov; 104(9):2967-75. PubMed ID: 15251988
[TBL] [Abstract][Full Text] [Related]
5. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway.
Sun J; Zhang D; Zheng Y; Zhao Q; Zheng M; Kovacevic Z; Richardson DR
Mol Pharmacol; 2013 Feb; 83(2):454-69. PubMed ID: 23188716
[TBL] [Abstract][Full Text] [Related]
6. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
7. Iron chelators can protect against oxidative stress through ferryl heme reduction.
Reeder BJ; Hider RC; Wilson MT
Free Radic Biol Med; 2008 Feb; 44(3):264-73. PubMed ID: 18215735
[TBL] [Abstract][Full Text] [Related]
8. Local delivery of iron chelators reduces in vivo remodeling of a calcium phosphate bone graft substitute.
Drager J; Sheikh Z; Zhang YL; Harvey EJ; Barralet JE
Acta Biomater; 2016 Sep; 42():411-419. PubMed ID: 27449336
[TBL] [Abstract][Full Text] [Related]
9. Chelation and mobilization of cellular iron by different classes of chelators.
Zanninelli G; Glickstein H; Breuer W; Milgram P; Brissot P; Hider RC; Konijn AM; Libman J; Shanzer A; Cabantchik ZI
Mol Pharmacol; 1997 May; 51(5):842-52. PubMed ID: 9145923
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer.
Richardson DR
Curr Med Chem; 2005; 12(23):2711-29. PubMed ID: 16305467
[TBL] [Abstract][Full Text] [Related]
11. Cellular iron homeostasis and therapeutic implications of iron chelators in cancer.
Raza M; Chakraborty S; Choudhury M; Ghosh PC; Nag A
Curr Pharm Biotechnol; 2014; 15(12):1125-40. PubMed ID: 25496094
[TBL] [Abstract][Full Text] [Related]
12. Iron chelators in cancer chemotherapy.
Buss JL; Greene BT; Turner J; Torti FM; Torti SV
Curr Top Med Chem; 2004; 4(15):1623-35. PubMed ID: 15579100
[TBL] [Abstract][Full Text] [Related]
13. The role of iron chelation in cancer therapy.
Buss JL; Torti FM; Torti SV
Curr Med Chem; 2003 Jun; 10(12):1021-34. PubMed ID: 12678674
[TBL] [Abstract][Full Text] [Related]
14. The role of iron in cell cycle progression and the proliferation of neoplastic cells.
Le NT; Richardson DR
Biochim Biophys Acta; 2002 Oct; 1603(1):31-46. PubMed ID: 12242109
[TBL] [Abstract][Full Text] [Related]
15. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
16. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin.
Zaman K; Ryu H; Hall D; O'Donovan K; Lin KI; Miller MP; Marquis JC; Baraban JM; Semenza GL; Ratan RR
J Neurosci; 1999 Nov; 19(22):9821-30. PubMed ID: 10559391
[TBL] [Abstract][Full Text] [Related]
17. New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases.
Nuñez MT; Chana-Cuevas P
Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30347635
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
Bendova P; Mackova E; Haskova P; Vavrova A; Jirkovsky E; Sterba M; Popelova O; Kalinowski DS; Kovarikova P; Vavrova K; Richardson DR; Simunek T
Chem Res Toxicol; 2010 Jun; 23(6):1105-14. PubMed ID: 20521781
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Macromolecular Iron Chelators.
Bulbake U; Singh A; Domb AJ; Khan W
Curr Med Chem; 2019; 26(2):323-334. PubMed ID: 30182850
[TBL] [Abstract][Full Text] [Related]
20. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
